74 related articles for article (PubMed ID: 25448574)
1. Self-assembled drug delivery systems. Part 8: In vitro/in vivo studies of the nanoassemblies of cholesteryl-phosphonyl gemcitabine.
Li M; Qi S; Jin Y; Dong J
Int J Pharm; 2015 Jan; 478(1):124-130. PubMed ID: 25448574
[TBL] [Abstract][Full Text] [Related]
2. Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies.
Jin Y; Lian Y; Du L; Wang S; Su C; Gao C
Int J Pharm; 2012 Jul; 430(1-2):276-81. PubMed ID: 22486963
[TBL] [Abstract][Full Text] [Related]
3. Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma.
Du L; Zhang B; Lei Y; Wang S; Jin Y
Biomed Pharmacother; 2016 Apr; 79():208-14. PubMed ID: 27044830
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic nanoassemblies of 1-O-octodecyl-2-conjugated linoleoyl-sn-glycero-3-phosphatidyl gemcitabine with phospholipase A
Zuo J; Tong L; Du L; Yang M; Jin Y
Colloids Surf B Biointerfaces; 2017 Apr; 152():467-474. PubMed ID: 28187380
[TBL] [Abstract][Full Text] [Related]
5. Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release.
Du L; Wu L; Jin Y; Jia J; Li M; Wang Y
Int J Pharm; 2014 Sep; 472(1-2):1-9. PubMed ID: 24929012
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
7. Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine.
Jin Y; Xing L; Tian Y; Li M; Gao C; Du L; Dong J; Chen H
Int J Pharm; 2009 Oct; 381(1):40-8. PubMed ID: 19646518
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
[TBL] [Abstract][Full Text] [Related]
9. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
10. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
11. Molecular self-assembly of amphiphilic cyclic phosphoryl gemcitabine with different N-fatty acyl tails and enhanced anticancer effects of the self-assembled nanostructures.
Jin Y; Wang S; Yao W; Du L
Colloids Surf B Biointerfaces; 2015 Sep; 133():356-61. PubMed ID: 26143151
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
Liang TJ; Zhou ZM; Cao YQ; Ma MZ; Wang XJ; Jing K
Int J Pharm; 2016 Nov; 513(1-2):564-571. PubMed ID: 27613255
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
14. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
[TBL] [Abstract][Full Text] [Related]
15. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
16. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization.
Li T; Chen L; Deng Y; Liu X; Zhao X; Cui Y; Shi J; Feng R; Song Y
Drug Dev Ind Pharm; 2017 Dec; 43(12):2016-2025. PubMed ID: 28760000
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
Thompson BR; Shi J; Zhu HJ; Smith DE
Biochem Pharmacol; 2020 Oct; 180():114127. PubMed ID: 32603666
[TBL] [Abstract][Full Text] [Related]
20. Self-assembled drug delivery systems: Part 3. In vitro/in vivo studies of the self-assembled nanoparticulates of cholesteryl acyl didanosine.
Jin Y; Ai P; Xin R; Tian Y; Dong J; Chen D; Wang W
Int J Pharm; 2009 Feb; 368(1-2):207-14. PubMed ID: 19007871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
